


COMPARE-1 CLINICAL TRIAL TWO YEAR RESULTS FROM PILOT PHASE PRESENTED AT LINC 2019¹

TRIAL DESIGN:

WORLD'S FIRST Head-to-Head Prospective, **RANDOMIZED (1:1) CONTROLLED** Trial comparing the lower dose Paclitaxel RANGER DCB (2 µg/mm²) to the higher dose Paclitaxel IN.PACT DCB (3.5 µg/mm²)

TWO YEAR RESULTS:



Similar Patency (p=0.57*), with significantly less drug

The new generation, lower dose, Ranger DCB demonstrated similar Patency with significantly less drug compared to the higher dose IN.PACT DCB.

COMPARE-1 CLINICAL TRIAL

TRIAL DETAILS

OBJECTIVE:

To compare two different Paclitaxel coated balloons (with different coatings and different Paclitaxel dose density) in the treatment of high grade stenotic or occluded lesions in SFA and/or PPA in PAD patients with Rutherford class 2-4.

TRIAL DESIGN:

- Prospective, multicenter, randomized trial
- Randomization 1:1
- Phase 1: Pilot Study (150 patients)
- Phase 2: Extension (up to 414 patients) for testing of a formal non-inferiority hypothesis
- Stratification according to lesion length
- Follow-up clinical visits at 6, 12, 24 months

	Ranger™	IN.PACT™	
Drug Dose	2.0 μg/mm²	3.5 μg/mm²	
Longest Length Available	200 mm	150 mm	
Platform	Sterling [™]	Admiral [™] or Pacific [™]	
Excipient	TransPax [™]	Urea	

BASELINE CHARACTERISTICS	Ranger™ (n=74)	IN.PACT™ (n=76)	p-value
Total Occlusions	39 %	45 %	0.5
Total Occlusion Length	111 mm	95 mm	0.5
Target Lesion Length	117 mm	122 mm	0.8
Moderate to Severe Calcification	58 %	61 %	0.7*
Diabetics	34 %	37%	0.7

* p-value includes all categories of calcification

KEY ENROLLMENT CRITERIA:

- Rutherford 2, 3 or 4
- Stenotic, restenotic or occlusive lesions (≥ 70% stenosis) in the native non-stented SFA/PPA
- No prior treatment with drug coated balloons or drug-eluting stents in the treated limb
- Lesion \leq 300 mm, RVD \geq 4 mm and \leq 6.5 mm

DEFINITIONS:

Patency — Core lab adjudicated (12 months):

Efficacy: patency rate after one year defined as absence of clinically driven Target Lesion Revascularization (due to symptoms and drop of ABI of \ge 20% or > 0.15 when compared to post-procedure) or restenosis with Peak Velocity Ratio > 2.4 evaluated by Duplex Ultrasound

Ranger[™] Paclitaxel Coated PTA Balloon Catheter is manufactured by Hemoteq AG and distributed by Boston Scientific Corporation. All cited trademarks are the property of their respective owners. **CAUTION:** The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. This material is not for use or distribution in France.



www.bostonscientific.eu

© 2019 Boston Scientific Corporation or its affiliates. All rights reserved. PI-601911-AA JAN2019